Intellia Therapeutics, Inc. Stockholders Equity

Quick Answer

Intellia Therapeutics, Inc. reported Stockholders Equity of $671.39 million for fiscal year 2025.

Intellia Therapeutics, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $671.39M -23.0%
2024 $871.96M -17.0%
2023 $1.05B -15.0%
2022 $1.24B +18.8%
2021 $1.04B +97.4%
2020 $527.07M +95.3%
2019 $269.88M -2.9%
2018 $277.92M -7.5%
2017 $300.60M +43.3%
2016 $209.84M +1089.8%
2015 -$21.20M -380.2%
2014 $7.57M
2014 $0.00

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $748.42M -22.3% +4.6%
June 30, 2025 $715.25M -26.3% -8.3%
March 31, 2025 $779.92M -24.7% -10.6%
December 31, 2024 $871.96M -17.0% -9.4%
September 30, 2024 $962.62M -7.2% -0.9%
June 30, 2024 $971.06M -12.1% -6.3%
March 31, 2024 $1.04B -13.0% -1.3%
December 31, 2023 $1.05B -15.0% +1.2%
  • Intellia Therapeutics, Inc. showed a decrease of -23.0% in Stockholders Equity compared to the prior fiscal year.
  • The most recent figure is from Intellia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment